Resultats globals: 1 registres trobats en 0.01 segons.
Articles, 1 registres trobats
Articles 1 registres trobats  
1.
11 p, 1.4 MB Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma / Timmerman, John (UCLA Medical Center) ; Herbaux, Charles (Centre Hospitalier Régional Universitaire de Lille) ; Ribrag, Vincent (Institut Gustave Roussy (Villejuif, França)) ; Zelenetz, Andrew D. (Memorial Sloan Kettering Cancer Center) ; Houot, Roch (Unité dʼInvestigation Clinique) ; Neelapu, Sattva S. (The University of Texas MD Anderson Cancer Center) ; Logan, Theodore (Indiana University) ; Lossos, Izidore S. (Sylvester Comprehensive Cancer Center) ; Urba, Walter (Providence Cancer Center) ; Salles, Gilles (Université de Lyon) ; Ramchandren, Radhakrishnan (Karmanos Cancer Institute) ; Jacobson, Caron (Harvard Medical School) ; Godwin, John (Providence Cancer Center) ; Carpio Segura, Cecilia del Carmen (Universitat Autònoma de Barcelona. Departament de Medicina) ; Lathers, Deanne (Bristol-Myers Squibb) ; Liu, Yali (Bristol-Myers Squibb) ; Neely, Jaclyn (Bristol-Myers Squibb) ; Suryawanshi, Satyendra (Bristol-Myers Squibb) ; Koguchi, Yoshinobu (Providence Cancer Center) ; Levy, Ronald (Stanford University School of Medicine)
Urelumab, a fully human, non-ligand binding, CD137 agonist IgG4 monoclonal antibody, enhances T-cell and natural killer-cell antitumor activity in preclinical models, and may enhance cytotoxic activity of rituximab. [...]
2020 - 10.1002/ajh.25757
American Journal of Hematology, Vol. 95 (february 2020) , p. 510-520  

Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.